An Introduction to Epilepsy
Epilepsy is one of the most common neurological disorders, affecting around 50 million people worldwide. Advances in epilepsy imaging and treatment (e.g. ablative and neurostimulation procedures, and new antiepileptic drugs) have decreased seizure frequency and severity. Yet unmet needs remain with approximately 30% of people with epilepsy refractory to pharmacotherapies. Novel therapeutic targets include AMPA receptors, potassium channels and synaptic vesicle protein 2A. Ongoing developments and improved understanding of the genetics of epilepsy subtypes may provide patient-specific solutions.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Addressing unmet needs to improve outcomes for people with epilepsy
Keep up to date on the latest developments by watching this webinar discussing key issues in the treatment and management of severe epilepsy, focussing on: The key unmet medical needs that still exist for people with severe epilepsy. How the latest clinical trial results support emerging therapeutic options to address these unmet needs. Challenges and insights that the COVID-19 pandemic has revealed about the diagnosis, treatment and management of people with epilepsy. Part 1: Watch the webinar with three internationally renowned experts discussing key issues in the treatment and management of severe epilepsy Watch Now Part 2: Watch the interview providing the highlights of the webinar Watch Now
- Assess the main diagnostic approaches in epilepsy and the challenges that remain in the management and monitoring of the disease, particularly during the COVID-19 pandemic
- Recognize the key medical unmet needs that remain for people with epilepsy, especially with conditions that are often refractory to conventional anti-epileptic drugs, such as encephalopathic epilepsies
- Describe recent therapeutic developments in epilepsy, evaluate the supporting clinical evidence, and appreciate how they might impact quality of life beyond symptom control
Key developments in the diagnosis, treatment and understanding of childhood-onset, treatment-resistant epilepsies with Dr Antonietta Coppola & Dr Angel Aledo-Serrano
Watch this two-part activity discussing diagnostic and therapeutic advances in the field of childhood-onset treatment-resistant epilepsy from AES 2020 Part 1: Watch internationally renowned expert Dr Antonietta Coppola review key data from the conference focussing on genetic diagnosis and treatments Watch Now Part 2: Choose from two leading experts who discuss how data presented at the AES 2020 may affect daily practice Select An Interview
- Recognise the unmet needs and challenges that remain for people living with childhood-onset, treatment-resistant epilepsies.
- Understand the challenges that remain in the management and monitoring of the childhood-onset epilepsies, and be aware of the key diagnostic advances presented at AES 2020.
- Describe the key therapeutic developments for childhood-onset, treatment-resistant epilepsies presented at AES 2020.
Cenobamate for the Treatment of Focal Seizures
US Neurology. 2020;16(2):87–97 DOI: https://doi.org/10.17925/USN.2020.16.2.87
Epilepsy is a very common neurological disease, affecting more than 50 million people worldwide and 3.4 million people in the USA.1–3 Focal seizures, formerly partial-onset seizures, are the most common type, making up ≥60% of cases.4–6 Patients with epilepsy have an increased risk of morbidity and mortality, a decreased quality of life and are more likely […]
Cenobamate—The New Kid on the Block, Teaching More About Epilepsy Than Just Offering a New Treatment for Seizures
US Neurology. 2020;16(2):85–6 DOI: https://doi.org/10.17925/USN.2020.16.2.85
Dogma dictates that scientific literature should be couched in the third person, past tense. The idea is to obviate the potential to introduce personal bias that may accompany first person, present tense, which is creeping into modern scientific writing. This use of the first person, I am reliably told, followed wide adoption of blogging, in […]
Pat Penovich, AES 2020 – The Patient Experience With Diazepam Nasal Spray
It was a pleasure to talk to Pat Penovich (Minnesota Epilepsy Group, St. Paul, MN, USA) about the exit survey, of a Phase 3 study, assessing patient experience of using the diazepam nasal spray for seizure clusters. The abstract ‘Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit […]
Martin Brodie, CONy 2020 – Combination Antiepileptic Drug Therapy
It was a pleasure to speak with Martin Brodie (President, International Bureau for Epilepsy and co-Section Head of Epilepsy for CONy), who spoke with us on the topic of the debate session he participated in: Should combination antiepileptic drug (AED) therapy be offered immediately after failure of a single antiepileptic drug? Questions Could you tell […]
Can we reach our goals for seizure management in drug-resistant focal epilepsy?
Watch leading experts discuss aspects of the diagnosis and treatment of drug-resistant epilepsy, including up-to-date clinical data.
- Recognize the impact of recurrent seizures in patients with drug-resistant epilepsy
- Outline the challenges associated with current standard of care approaches in the management of patients with drug-resistant epilepsy
- Assess how emerging anti-epileptic drugs might address the unmet treatment needs in patients with drug-resistant focal epilepsy
Ingrid Scheffer, AES 2020 – Long Term Efficacy and Safety of Fenfluramine in Patients with Dravet Syndrome
We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]
Kelly Knupp, AES 2020 – Fenfluramine for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome
We caught up with Kelly Knupp (University of Colorado, Anschutz Medical Campus, Children’s Hospital Colorado, CO, USA) to discuss the use of fenfluramine for the reduction of seizures associated with Lennox-Gastaut syndrome. (Clinical Trial Identifier: NCT03355209). The abstract ‘Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!